Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
Grant
US12577313B2
Kind: B2
Mar 17, 2026
Assignee
I-Mab Biopharma US Limited
Inventors
Wenqing Jiang, Lei Fang, Zhengyi Wang, Bingshi Guo, Eunyoung Park, Eunsil Sung, Byungje Sung
Abstract
Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
CPC Classifications
C07K 16/2878
C07K 16/28
C07K 2317/31
C07K 2317/52
C07K 2317/622
C07K 2317/92
C07K 2317/41
C07K 2317/55
C07K 2317/64
C07K 2317/71
C07K 2317/75
C07K 2317/56
C07K 2317/565
A61P 35/00
A61K 2039/505
Filing Date
2022-03-01
Application No.
17683869
Claims
15